• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Desferal (deferoxamine mesylate) injection

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – September 2010

 

Summary View

 

WARNINGS

  • Increases in serum creatinine (possibly dose-related), acute renal failure and renal tubular

disorders, associated with the administration of deferoxamine, have been reported in

postmarketing experience

ADVERSE REACTIONS

  • Hepatic: hepatic dysfunction

  • Urogenital: acute renal failure